RUNX1T1 and acute myeloid leukemia: Second, for favorable de novo AML cases in CR1, haplo-SCT could be used to improve outcomes in the following subgroup patients: i) t(8;21) AML cases who did not achieve major molecular remission (MMR)/MRD negativity, which were defined as >3-log reduction in RUNX1/RUNX1T1 transcripts (<0.4%) compared with the pretreatment baseline of 388% in Peking University Institute of Hematology, after the second consolidation therapy or those exhibiting the loss of MMR (defined as RUNX1/RUNX1T1 transcript levels >0.4% in MMR patients) within 6 months of achieving MMR (7, 61).